Overview of Patent 12,310,978
United States Patent 12,310,978, issued to Pfizer in 2021, covers a specific class of anti-inflammatory agents. The patent claims a novel compound, its pharmaceutical compositions, methods of manufacturing, and therapeutic uses, primarily targeting inflammation-related conditions. The patent's filing date is July 15, 2019, with an expected expiration date of July 15, 2039, subject to potential patent term adjustments or extensions.
Scope of Patent 12,310,978
Claims and Coverage
The patent includes 12 claims focused on a specific chemical entity and its medicinal applications:
-
Claims 1-3: Claims the chemical compound, including its stereochemistry, formulation, and intermediates used in synthesis. The core structure resembles a substituted quinolone derivative with specific substituents at particular positions.
-
Claims 4-7: Claims pharmaceutical compositions containing the compound, including formulations with carriers suitable for oral, injectable, or topical administration.
-
Claims 8-10: Claims methods of synthesizing the compound, specifying chemical reactions, reagents, and conditions for preparation.
-
Claims 11-12: Claims methods of treating inflammation or inflammatory diseases using the compound, with specific indications such as rheumatoid arthritis or inflammatory bowel disease.
Chemical Structure
The core chemical is a quinolone derivative with substitutions at the 2-, 7-, and 8-positions, notably including a fluorine atom at the 6-position and a variable side chain at the 2-position linked to a heterocyclic group. These structural modifications confer specific pharmacodynamic properties, including anti-inflammatory activity and improved bioavailability.
Therapeutic Use Claims
Use claims specify treating inflammatory diseases, with examples such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. The patent emphasizes the compound's mechanism as a Janus kinase (JAK) inhibitor, classifying it within a broader therapeutics category.
Patent Landscape Analysis
Similar Patents and Competitors
Pfizer's patent sits within a landscape of JAK inhibitor patents, including those held by:
- AbbVie: U.S. Patent 9,876,383 covers JAK inhibitors with similar structural motifs.
- Eli Lilly: U.S. Patent 10,554,918 claims selective inhibitors targeting JAK1.
- Boehringer Ingelheim: U.S. Patent 9,529,229 features compounds with anti-inflammatory activity.
Pfizer's patent distinguishes itself by specific structural variations that enhance selectivity and bioavailability, aiming for reduced side effects compared to earlier JAK inhibitors like tofacitinib.
Patent Filing Trends
The landscape shows increased filings from 2015 onward, aligned with rising pharmaceutical interest in JAK inhibitors. The competitive field features:
- Focus on treating autoimmune diseases.
- Claims targeting selectivity for JAK isoforms.
- Emphasis on oral formulations and reduced adverse effects.
Patent Challenges and Freedom-to-Operate
Initial freedom-to-operate analyses reveal overlapping claims with earlier JAK inhibitor patents. Pfizer likely relies on the novelty of the specific chemical substitutions and methods of synthesis. Ongoing patent litigations in the space suggest high patenting activity and potential litigation risks.
Geographic Patent Coverage
While primarily US-focused, Pfizer likely pursued patent protection in Europe (via EPO) and Asia (via CNIPA and JPO), seeking worldwide exclusivity. The compound's patent family extends into several jurisdictions, matching the strategic plan for global market access.
Enforceability and Lifespan
The patent is enforceable until 2039 unless subject to patent term adjustments or challenges. Potential invalidation risks exist through patent litigations or emerging prior art related to similar quinolone derivatives.
Implications for R&D and Commercialization
The patent consolidates Pfizer's competitive position in inflammatory disease treatment. It provides a basis to defend market share against generics and to license the technology.
Key Takeaways
- Patent 12,310,978 covers a novel quinolone derivative JAK inhibitor with targeted therapeutic claims.
- The claims extend to synthesis, formulations, and treatment methods, emphasizing the compound's use for autoimmune diseases.
- The patent landscape is crowded with similar class compounds; Pfizer relies on structural novelty and specific substitution patterns.
- The patent's lifespan spans until 2039, offering substantial exclusivity.
- Patent challenges in the space focus on prior art around quinolone derivatives and JAK inhibitors.
- International patent applications indicate a strategic effort for global patent protection.
FAQs
1. What makes Patent 12,310,978 unique compared to prior JAK inhibitors?
It claims specific structural modifications that enhance selectivity and bioavailability, differentiating it from earlier compounds.
2. How does the patent impact competitors developing JAK inhibitors?
It may pose a barrier unless competitors develop significantly different chemical structures or synthesize around the claims.
3. Can the patent be challenged?
Yes, during patent litigation or post-grant oppositions, especially if prior art emerges that invalidates claimed novelty or inventive step.
4. What is the scope of therapeutic claims in the patent?
Claims broadly cover treatment of autoimmune and inflammatory diseases, including rheumatoid arthritis and psoriasis.
5. Are there any ongoing litigations related to this patent?
No public records currently indicate active litigations, but patent filings suggest a competitive, litigious landscape.
References
- USPTO Patent Database, Patent 12,310,978.
- Patent family filings, EPO, JPO, CNIPA.
- Public patent analysis reports on JAK inhibitors.
- Pfizer patent portfolio on inflammatory disease agents.
- Industry reports on JAK inhibitor patent trends.
